生物制药公司Altimmune宣布,计划将此次融资所得净收益专项用于支持其针对代谢相关脂肪性肝炎(MASH)的即将开展的三期临床试验。根据公司最新规划,该项关键性三期试验预计将于今年下半年正式启动。
生物制药公司Altimmune宣布,计划将此次融资所得净收益专项用于支持其针对代谢相关脂肪性肝炎(MASH)的即将开展的三期临床试验。根据公司最新规划,该项关键性三期试验预计将于今年下半年正式启动。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.